Ascendis Pharma details warrant exercises, capital boost

Ascendis Pharma A/S reports the closing of a warrant exercise window for its outstanding warrants linked to ordinary shares.

Accepted by SEC EDGAR 06/29/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascendis Pharma A/S reports the closing of a warrant exercise window for its outstanding warrants linked to ordinary shares. During this window, holders exercised warrants resulting in registered share capital increases of nominal DKK 177,267.

This raised the company’s total share capital to nominal DKK 66,189,926 through the issuance of 177,267 new ordinary shares. Ascendis received average cash consideration of approximately USD $121.57 per share, based on the DKK-USD exchange rate on June 29, 2026. The company’s articles of association were updated to reflect the new capital and are included as an exhibit.

Key Figures

New shares issued: 177,267 shares Capital increase (nominal): DKK 177,267 Total nominal share capital: DKK 66,189,926 +1 more

4 metrics

New shares issued 177,267 shares Ordinary shares issued from warrant exercises during window

Capital increase (nominal) DKK 177,267 Aggregate nominal share capital increase from exercised warrants

Total nominal share capital DKK 66,189,926 Share capital after warrant-driven capital increase

Average cash per share USD $121.57 per share Average cash consideration based on DKK-USD rate on June 29, 2026

Key Terms

warrants, exercise window, articles of association, Form 6-K, +2 more

6 terms

warrants financial

"an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise window financial

"On June 29, 2026, an exercise window closed for the Company’s outstanding warrants"

articles of association regulatory

"The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1."

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

registration statements on Form S-8 regulatory

"incorporated by reference into the registration statements on Form S-8"

Form F-3 regulatory

"and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascendis Pharma (ASND) announce in this Form 6-K?

Ascendis Pharma reported the closing of a warrant exercise window that resulted in new shares being issued and a higher nominal share capital. The filing also updates its articles of association to reflect these changes and incorporates the report into existing registration statements.

How many new Ascendis Pharma shares were issued from warrant exercises?

The company issued 177,267 new ordinary shares from the exercise of warrants during the window. These shares carry a nominal value of DKK 1 each and contributed to a nominal share capital increase of DKK 177,267, bringing total nominal capital to DKK 66,189,926.

What cash did Ascendis Pharma receive per share from the warrant exercises?

Ascendis Pharma received average cash consideration of approximately USD $121.57 per share for the newly issued ordinary shares. This amount is based on the DKK-USD exchange rate on June 29, 2026 and reflects the cash inflow tied to the exercised warrants.

How did the warrant exercises affect Ascendis Pharma’s nominal share capital?

The warrant exercises increased Ascendis Pharma’s nominal share capital by DKK 177,267. After this increase, the company’s total nominal share capital reached DKK 66,189,926, showing the cumulative effect of the new 177,267 ordinary shares issued during the exercise window.

Were Ascendis Pharma’s articles of association changed in this filing?

Yes. The company amended its articles of association to reflect the higher nominal share capital following the warrant exercises. The updated articles of association are attached as Exhibit 1.1, providing formal documentation of the revised capital structure and related corporate details.

How is this Ascendis Pharma 6-K related to existing registration statements?

This report is incorporated by reference into Ascendis Pharma’s registration statements on Form S-8 and Form F-3. That means the information about the warrant exercises and capital increase becomes part of those registration documents from the date this report is filed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Closing of Warrant Exercise Window

On June 29, 2026, an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares, nominal value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 177,267 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 66,189,926 through the issuance of 177,267 ordinary shares against average cash consideration of approximately USD $121.57 per share, based on the DKK-USD exchange rate on June 29, 2026. The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: June 29, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 497.9 KB